CARL BLACK: Open Payments
NPI 1336723840 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,812 in 82 payments from 16 companies in 2025. Trend: 2023 $2,330 · 2024 $1,851 · 2025 $1,812
Food & beverage: $1,812
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $271 |
| GlaxoSmithKline, LLC. | 10 | $231 |
| AstraZeneca Pharmaceuticals LP | 10 | $215 |
| PFIZER INC. | 9 | $189 |
| Lilly USA, LLC | 6 | $150 |
| Astellas Pharma US Inc | 7 | $149 |
| ABBVIE INC. | 9 | $141 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $91 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $86 |
| Dexcom, Inc. | 2 | $77 |
Products named: TRELEGY ELLIPTA, NURTEC ODT, Ozempic, MOUNJARO, Veozah, JARDIANCE, BREZTRI, Kerendia.
Industry payments across PA — which companies pay providers there.
